10 Questions
What was the trend in CD20+ B-cell counts among all participants with prior rituximab use during the open-label period (>Week 28)?
Decreased
How was UPLIZNA generally tolerated in the study?
Well
What was the percentage of participants with prior rituximab use who experienced treatment-related adverse events?
53%
How many participants with prior rituximab use experienced treatment discontinuation due to adverse events?
1
What percentage of participants with no prior rituximab use experienced serious adverse events?
18%
Were there any deaths reported among the 17 rituximab-experienced participants?
No
What was the percentage of participants with prior rituximab use who experienced grade >3 adverse events?
29%
How many rituximab-experienced participants had serious events that were also related to UPLIZNA?
2
Did prior rituximab use appear to be associated with an increased rate of serious or grade >3 infections in the study?
No
What was the total number of participants with prior rituximab use in the study?
17
Explore the summary of attack data in N-MOmentum study participants who switched from rituximab to inebilizumab. Understand the occurrences of attacks during different treatment periods and the impact on participants.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
